
The study's aim was to compare the efficacy and safety of intravenous zzso zzso and zzso zzso as zzso therapy in a clinical sample of active zzso zzso or zzso zzso multiple sclerosis zzso zzso was administered at a dosage of 8 zzso monthly for 3 months, then every 3 months, until a dosage of 120 zzso was zzso zzso was administered at a dosage of 700 zzso monthly for 12 months, then zzso for another 24 zzso We used the zzso zzso to assess time to the first zzso in zzso and SP patients with zzso and time to progression on the Expanded zzso zzso zzso zzso in all the zzso zzso was assessed at baseline and after 12 zzso Moreover, side effects were zzso Seventy-five patients received zzso zzso zzso 44 zzso and 78 zzso (15 zzso 63 zzso The two groups differ only in terms of a significantly higher proportion of zzso patients in the zzso zzso After a mean follow-up of zzso years there was no significant difference in terms of time to the first zzso zzso zzso years, zzso zzso years; zzso whereas time to disease progression was slightly shorter in zzso than in zzso group zzso zzso years, zzso zzso years; zzso After 12 months of treatment, active zzso scans were reduced by zzso in zzso and zzso in zzso patients zzso zzso due to side effects was more frequent in zzso zzso However, the overall zzso profile was acceptable in both zzso 

